ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives $3.30 Average PT from Brokerages

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have been given a consensus rating of “Moderate Buy” by the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $3.30.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of ALX Oncology in a research report on Friday.

ALX Oncology Price Performance

ALXO stock opened at $1.75 on Friday. The firm has a market cap of $93.71 million, a PE ratio of -0.80 and a beta of 1.21. The company has a debt-to-equity ratio of 0.11, a quick ratio of 4.52 and a current ratio of 4.52. The firm’s fifty day moving average is $1.41 and its 200 day moving average is $0.83. ALX Oncology has a one year low of $0.40 and a one year high of $2.27.

ALX Oncology (NASDAQ:ALXO) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.03). On average, research analysts forecast that ALX Oncology will post -2.76 EPS for the current year.

Insider Transactions at ALX Oncology

In related news, CEO Jason Lettmann acquired 71,163 shares of the firm’s stock in a transaction on Wednesday, September 17th. The shares were acquired at an average cost of $1.08 per share, with a total value of $76,856.04. Following the completion of the acquisition, the chief executive officer directly owned 305,121 shares in the company, valued at approximately $329,530.68. This trade represents a 30.42% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 21.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ALX Oncology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Invesco Ltd. purchased a new position in ALX Oncology during the first quarter valued at $46,000. AQR Capital Management LLC lifted its stake in shares of ALX Oncology by 183.6% in the first quarter. AQR Capital Management LLC now owns 119,050 shares of the company’s stock worth $74,000 after buying an additional 77,065 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of ALX Oncology in the second quarter worth about $84,000. Nuveen LLC purchased a new position in shares of ALX Oncology in the first quarter worth about $103,000. Finally, Acadian Asset Management LLC lifted its stake in shares of ALX Oncology by 16.8% in the first quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company’s stock worth $806,000 after buying an additional 186,883 shares in the last quarter. 97.97% of the stock is owned by hedge funds and other institutional investors.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.